These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 37734338)
21. Acceptability and use of a dapivirine vaginal ring in a phase III trial. Montgomery ET; van der Straten A; Chitukuta M; Reddy K; Woeber K; Atujuna M; Bekker LG; Etima J; Nakyanzi T; Mayo AJ; Katz A; Laborde N; Grossman CI; Soto-Torres L; Palanee-Phillips T; Baeten JM; AIDS; 2017 May; 31(8):1159-1167. PubMed ID: 28441175 [TBL] [Abstract][Full Text] [Related]
22. The Influence of Perceived Dapivirine Vaginal Ring Effectiveness on Social Disclosure and Ring Adherence. Stoner MCD; Brown ER; Palanee-Phillips T; Mansoor LE; Tembo T; Nair G; Akello C; Seyama L; Jeenarain N; Naidoo L; Mgodi N; Hunidzarira P; Chitukuta M; van der Straten A; AIDS Behav; 2021 Dec; 25(12):4169-4179. PubMed ID: 33939034 [TBL] [Abstract][Full Text] [Related]
23. Hygiene, Blood Flow, and Vaginal Overload: Why Women Removed an HIV Prevention Vaginal Ring During Menstruation in Malawi, South Africa, Uganda and Zimbabwe. Duby Z; Katz AWK; Browne EN; Mutero P; Etima J; Zimba CC; Woeber K; Atujuna M; Reddy K; van der Straten A; AIDS Behav; 2020 Feb; 24(2):617-628. PubMed ID: 31030301 [TBL] [Abstract][Full Text] [Related]
24. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness. Glaubius R; Ding Y; Penrose KJ; Hood G; Engquist E; Mellors JW; Parikh UM; Abbas UL J Int AIDS Soc; 2019 May; 22(5):e25282. PubMed ID: 31074936 [TBL] [Abstract][Full Text] [Related]
25. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention. Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240 [TBL] [Abstract][Full Text] [Related]
26. Acceptability of the dapivirine vaginal ring for HIV-1 prevention among women reporting engagement in transactional sex. Browne EN; Torjesen K; Mirembe BG; Palanee-Phillips T; Jeenarain N; Chitukuta M; Stoner MCD; Mansoor LE; Reddy K; Tauya TT; Naidoo L; Siva S; Richardson B; Dadabhai S; Seyama L; Soto-Torres L; van der Straten A; AIDS Care; 2024 Jan; 36(1):80-86. PubMed ID: 37066990 [TBL] [Abstract][Full Text] [Related]
27. Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial. Nair G; Celum C; Szydlo D; Brown ER; Akello CA; Nakalega R; Macdonald P; Milan G; Palanee-Phillips T; Reddy K; Tahuringana E; Muhlanga F; Nakabiito C; Bekker LG; Siziba B; Hillier SL; Baeten JM; Garcia M; Johnson S; McClure T; Levy L; Livant E; Jacobson C; Soto-Torres L; van der Straten A; Hosek S; Rooney JF; Steytler J; Bunge K; Parikh U; Hendrix C; Anderson P; Ngure K; Lancet HIV; 2023 Dec; 10(12):e779-e789. PubMed ID: 37898146 [TBL] [Abstract][Full Text] [Related]
28. Ring-ing in the Future: Participant and Male Partner Perspectives Regarding Future Use of the Dapivirine Vaginal Ring for HIV Prevention. Reddy K; Mathebula F; Katz A; Luecke E; Tenza S; Palanee-Phillips T; Garcia M; Mansoor LE; Naidoo S; Morar N; Chitukuta M; Tsidya M; Montgomery ET; AIDS Behav; 2022 Jun; 26(6):1923-1932. PubMed ID: 35064389 [TBL] [Abstract][Full Text] [Related]
29. Negative rumours about a vaginal ring for HIV-1 prevention in sub-Saharan Africa. Chitukuta M; Duby Z; Katz A; Nakyanzi T; Reddy K; Palanee-Phillips T; Tembo T; Etima J; Musara P; Mgodi NM; van der Straten A; Cult Health Sex; 2019 Nov; 21(11):1209-1224. PubMed ID: 30657023 [TBL] [Abstract][Full Text] [Related]
30. Impact of Partner-Related Social Harms on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III Trial. Palanee-Phillips T; Roberts ST; Reddy K; Govender V; Naidoo L; Siva S; Gafoor Z; Pather A; Matovu F; Hlahla K; Makanani B; Nair G; Schwartz K; Torjesen K; Brown E; Soto-Torres L; Baeten J; Montgomery ET J Acquir Immune Defic Syndr; 2018 Dec; 79(5):580-589. PubMed ID: 30239426 [TBL] [Abstract][Full Text] [Related]
31. Correlates of Dapivirine Vaginal Ring Acceptance among Women Participating in an Open Label Extension Trial. Mirembe BG; Cabrera MV; van der Straten A; Nakalega R; Cobbing M; Mgodi NM; Palanee-Phillips T; Mayo AJ; Dadabhai S; Mansoor LE; Siva S; Nair G; Chinula L; Akello CA; Nakabiito C; Soto-Torres LE; Baeten JM; Brown ER AIDS Behav; 2023 Mar; 27(3):1030-1043. PubMed ID: 36066762 [TBL] [Abstract][Full Text] [Related]
32. Vaginal Ring Use in a Phase 3 Microbicide Trial: A Comparison of Objective Measures and Self-reports of Non-adherence in ASPIRE. Mensch BS; Richardson BA; Husnik M; Brown ER; Kiweewa FM; Mayo AJ; Baeten JM; Palanee-Phillips T; van der Straten A; AIDS Behav; 2019 Feb; 23(2):504-512. PubMed ID: 30218318 [TBL] [Abstract][Full Text] [Related]
33. Acceptability of the Dapivirine Vaginal Ring and Oral Truvada Among African Users in Late-Stage of Pregnancy. Montgomery ET; Hawley I; Fairlie L; Bunge K; Mathebula F; Etima J; Mutero P; Senyama L; Mayo A; Stoner MCD; Piper J; Balan I; van der Straten A AIDS Behav; 2024 Mar; 28(3):963-973. PubMed ID: 37932492 [TBL] [Abstract][Full Text] [Related]
34. The relationship between vaginal ring use and intimate partner violence and social harms: formative research outcomes from the CHARISMA study in Johannesburg, South Africa. Hartmann M; Palanee-Phillips T; O'Rourke S; Adewumi K; Tenza S; Mathebula F; Wagner D; Ayub A; Montgomery ET AIDS Care; 2019 Jun; 31(6):660-666. PubMed ID: 30309246 [TBL] [Abstract][Full Text] [Related]
35. The dapivirine vaginal ring from the perspective of married men in Uganda. Kabarambi A; Kusemererwa S; Krogstad E; Mayaud P; Seeley J; Mugisha J; Gafos M Afr J AIDS Res; 2021 Mar; 20(1):53-60. PubMed ID: 33632073 [No Abstract] [Full Text] [Related]
36. Baseline preferences for oral pre-exposure prophylaxis (PrEP) or dapivirine intravaginal ring for HIV prevention among adolescent girls and young women in South Africa, Uganda and Zimbabwe (MTN-034/IPM-045 study). Ngure K; Friedland BA; Szydlo DW; Roberts ST; Garcia M; Levy L; Akello CA; Reddy K; Palanee-Phillips T; Macdonald P; Siziba B; Soto-Torres L; Hosek S; Hillier SL; Nair G; Celum C; van der Straten A PLoS One; 2023; 18(6):e0287525. PubMed ID: 37352296 [TBL] [Abstract][Full Text] [Related]
37. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial. Brown ER; Hendrix CW; van der Straten A; Kiweewa FM; Mgodi NM; Palanee-Philips T; Marzinke MA; Bekker LG; Soto-Torres L; Hillier SL; Baeten JM; J Int AIDS Soc; 2020 Nov; 23(11):e25634. PubMed ID: 33206462 [TBL] [Abstract][Full Text] [Related]
38. Pregnancy and Infant Outcomes Among Women Using the Dapivirine Vaginal Ring in Early Pregnancy. Makanani B; Balkus JE; Jiao Y; Noguchi LM; Palanee-Phillips T; Mbilizi Y; Moodley J; Kintu K; Reddy K; Kabwigu S; Jeenariain N; Harkoo I; Mgodi N; Piper J; Rees H; Scheckter R; Beigi R; Baeten JM J Acquir Immune Defic Syndr; 2018 Dec; 79(5):566-572. PubMed ID: 30383589 [TBL] [Abstract][Full Text] [Related]
39. U.S. Women Need the Dapivirine Ring, Too: FDA as Structural Barrier to HIV Prevention for Women. Gollub EL; Vaughan R AIDS Educ Prev; 2022 Aug; 34(4):311-324. PubMed ID: 35994576 [TBL] [Abstract][Full Text] [Related]
40. The Power of the Shared Experience: MTN-020/ASPIRE Trial Participants' Descriptions of Peer Influence on Acceptability of and Adherence to the Dapivirine Vaginal Ring for HIV Prevention. Katz AWK; Naidoo K; Reddy K; Chitukuta M; Nabukeera J; Siva S; Zimba C; Montgomery ET AIDS Behav; 2020 Aug; 24(8):2387-2399. PubMed ID: 31980993 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]